Grifols, a Spanish healthcare company that recently moved its corporate treasury activities from Barcelona to Dublin, has acquired a 49 per cent stake in the US-based Interstate Blood Bank (IBB) for $100 million (€88m).
The company has also entered into an option agreement to purchase the remaining 51 per cent stake for an additional $100 million, and has agreed to pay $10 million to exercise the call option.
Grifols, which employs 14,737 employees worldwide, announced 140 jobs with a new $100 million investment in its biosciences division global operations centre in Dublin last October. It followed this up last month with a further €85 million investment in the Dublin plant.
The principal business of the Memphis-headquartered IBB is the collection of plasma for the plasma fractionation industry. The deal for the company is expected to close within a month once clearance from US anti-trust authorities has been granted.
Grifols announced 2015 revenues that rose 17.3 per cent to €3.95 billion with net profit up 13.2 per cent to €532 million.
Full-year earnings before interest, taxes, depreciation and amortisation (ebitda) was up 11 per cent to €1.16 billion with an ebitda margin of 29.5 per cent.
